IN2015DN00370A - - Google Patents

Info

Publication number
IN2015DN00370A
IN2015DN00370A IN370DEN2015A IN2015DN00370A IN 2015DN00370 A IN2015DN00370 A IN 2015DN00370A IN 370DEN2015 A IN370DEN2015 A IN 370DEN2015A IN 2015DN00370 A IN2015DN00370 A IN 2015DN00370A
Authority
IN
India
Prior art keywords
mammal
therapeutically effective
effective dose
jak
inhibitor
Prior art date
Application number
Other languages
English (en)
Inventor
Andrea J Gonzales
Sallie B Cosgrove
Phyllis B Malpas
Michael Rolf Stegemann
Wendy Turner Collard
Original Assignee
Zoetis Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48901189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2015DN00370(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Llc filed Critical Zoetis Llc
Publication of IN2015DN00370A publication Critical patent/IN2015DN00370A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
IN370DEN2015 2012-07-20 2013-07-18 IN2015DN00370A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261674289P 2012-07-20 2012-07-20
US201361815803P 2013-04-25 2013-04-25
PCT/US2013/051015 WO2014015107A1 (en) 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors

Publications (1)

Publication Number Publication Date
IN2015DN00370A true IN2015DN00370A (pt) 2015-06-12

Family

ID=48901189

Family Applications (1)

Application Number Title Priority Date Filing Date
IN370DEN2015 IN2015DN00370A (pt) 2012-07-20 2013-07-18

Country Status (24)

Country Link
US (1) US9522151B2 (pt)
EP (1) EP2874630B1 (pt)
JP (2) JP6022063B2 (pt)
KR (2) KR20150028299A (pt)
CN (2) CN104470525A (pt)
AU (1) AU2013292547B2 (pt)
BR (1) BR112015000808A2 (pt)
CA (1) CA2878867C (pt)
CY (1) CY1121436T1 (pt)
DK (1) DK2874630T3 (pt)
ES (1) ES2707627T3 (pt)
HK (2) HK1209314A1 (pt)
HR (1) HRP20182088T1 (pt)
HU (1) HUE042771T2 (pt)
IN (1) IN2015DN00370A (pt)
LT (1) LT2874630T (pt)
MX (1) MX360857B (pt)
NZ (1) NZ703152A (pt)
PL (1) PL2874630T3 (pt)
PT (1) PT2874630T (pt)
RS (1) RS58242B1 (pt)
SI (1) SI2874630T1 (pt)
WO (1) WO2014015107A1 (pt)
ZA (1) ZA201500134B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA38347A1 (fr) 2013-02-22 2017-10-31 Pfizer Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak)
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
JP7096592B2 (ja) * 2016-02-16 2022-07-06 ワシントン・ユニバーシティ Jak阻害剤およびこれらの利用
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
CA3127892A1 (en) * 2019-01-30 2020-08-06 Gargamel (Zhuhai) Biotech Ltd. Jak inhibitor and preparation method thereof
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
EP4263559A1 (en) 2020-12-18 2023-10-25 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID26698A (id) 1998-06-19 2001-02-01 Pfizer Prod Inc SENYAWA-SENYAWA PIROLO [2,3-d] PIRIMIDINA
DK2384326T3 (da) 2008-08-20 2014-05-05 Zoetis Llc Pyrrolo[2,3-d]pyrimidinforbindelser

Also Published As

Publication number Publication date
HRP20182088T1 (hr) 2019-02-08
KR20170034949A (ko) 2017-03-29
MX2015000871A (es) 2015-05-07
CN104470525A (zh) 2015-03-25
US20150126535A1 (en) 2015-05-07
EP2874630B1 (en) 2018-12-05
CA2878867A1 (en) 2014-01-23
HUE042771T2 (hu) 2019-07-29
AU2013292547A1 (en) 2015-01-22
EP2874630A1 (en) 2015-05-27
LT2874630T (lt) 2019-02-11
MX360857B (es) 2018-11-20
NZ703152A (en) 2016-03-31
AU2013292547B2 (en) 2017-05-04
HK1209314A1 (en) 2016-04-01
CA2878867C (en) 2018-01-09
CY1121436T1 (el) 2020-05-29
DK2874630T3 (en) 2019-01-28
HK1252083A1 (zh) 2019-05-17
ZA201500134B (en) 2016-08-31
PT2874630T (pt) 2019-01-31
CN108354938A (zh) 2018-08-03
JP2015522620A (ja) 2015-08-06
RS58242B1 (sr) 2019-03-29
JP2017019816A (ja) 2017-01-26
PL2874630T3 (pl) 2019-04-30
SI2874630T1 (sl) 2019-04-30
KR20150028299A (ko) 2015-03-13
US9522151B2 (en) 2016-12-20
ES2707627T3 (es) 2019-04-04
JP6022063B2 (ja) 2016-11-09
BR112015000808A2 (pt) 2017-06-27
WO2014015107A1 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
IN2015DN00370A (pt)
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
MX2021002406A (es) Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica.
UA114090C2 (uk) Сполуки, що інгібують металоферменти
ECSP14013159A (es) Compuestos inhibidores de metaloenzimas
MX2020004183A (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
IN2014MN00093A (pt)
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
IN2014MN01378A (pt)
IN2014KN02601A (pt)
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
MX2013012285A (es) Anticuerpo anti-b7-h3.
MX2014004766A (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
MX2013008192A (es) Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
IN2014CN04634A (pt)
WO2012104823A3 (en) Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
MX368474B (es) Uso de benralizumab para mejorar síntomas de asma.
PH12016500903A1 (en) Novel methods for treating neurodegenerative diseases
MX2014003883A (es) Inhibidores de monoacilglicerol lipasa para el tratamiento de enfermedades metabolicas y transtornos relacionados.
MX347541B (es) Analogos de acido sialico.
IN2014DN03010A (pt)
CR20140289A (es) Derivados de quinolina como inhibidores de la enzima pde10a